Summary
Updated Aug 31, 2026
Jeffrey S. Mathiesen is Director of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). 3 SEC Form 4 filings on record going back to 2025, most recently on 7 April 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Jeffrey S. Mathiesen has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Jeffrey S. Mathiesen go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Jeffrey S. Mathiesen files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- David J. Wambeke - $670K of NMTC open-market activity in the last 12 months
- Mark Christianson - $77K of NMTC open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Jeffrey S. Mathiesen?
Jeffrey S. Mathiesen is a corporate insider, tracked as Director of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Jeffrey S. Mathiesen last file a Form 4?
The most recent primary Form 4 on record is dated 7 April 2026, one of 3 filings going back to 2025.
Where can I see all of Jeffrey S. Mathiesen's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Jeffrey S. Mathiesen and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial